个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
刘福全教授是介入医学专家。从事介入医学专业30多年，是国内最早应用和熟练掌握介入技术及介入医学科学知识诊治肝脏疾病、血管病与肿瘤的专家之一，曾经在国外深造。是最早组织成立独立的介入治疗专业和科室（包括病房45张床、门诊、手术室及研究室）的专家及科主任之一，使本人及相关医生真正成为医学影像与临床专业紧密及有机结合的典范，并形成了以肝脏、肿瘤及血管疾病为特色，以肝硬化门静脉高压及布加综合征为具有鲜明稳定研究方向的学科及学术团队。带领团队完成介入诊疗手术达40000余例次，完成肝硬化门静脉高压介入手术7000余例（TIPS手术5000多例，每年完成300多例），布加综合征2000余例，对肝硬化门静脉高压的诊治有独到的研究，如国内最早应用经皮肝穿胃冠状静脉栓塞术治疗食道胃底静脉曲张出血（1993年）、对国内最大及随访时间最长的一组TIPS病例进行了系统分析和总结、率先总结了急性肝静脉完全堵塞型布加综合征重度黄疸的TIPS治疗、首次研究TIPS预分流通道原始肝组织的获取及相关性研究、建立肝硬化门静脉高压标本库、建立第二分流通道、门静脉血栓的常规、个体化及特殊的介入治疗、建立大动物肝硬化门静脉高压模型及TIPS联合游离放射粒子植入术治疗门静脉主干癌栓（国外国际大会专题报告并获奖）等。
科室正式医生8名，均是技术骨干，主任医师2名，副主任医师1名。
| 成员姓名 | 学历学位 | 职称 | 专业特长 |
| 刘福全 | 硕士研究生 | 主任医师 | 门脉高压、肝硬化、布加综合征、肿瘤、血管等相关疾病的介入治疗 |
| 岳振东 | 本科 | 主任医师 | 门脉高压、肝硬化、布加综合征、肿瘤、血管等相关疾病的介入治疗 |
| 王磊 | 硕士研究生 | 副主任医师 | 肝硬化、布加综合征、肝小静脉闭塞症、门脉高压、肿瘤等疾病的介入治疗 |
| 范振华 | 硕士研究生 | 主治医师 | 肝硬化、布加综合征、肝小静脉闭塞症、门脉高压、肿瘤等疾病的介入治疗 |
| 王修琪 | 硕士研究生 | 主治 医师 | 肝硬化、布加综合征、肝小静脉闭塞症、门脉高压、肿瘤等疾病的介入治疗 |
| 吴一凡 | 硕士研究生 | 住院医师 | 门脉高压、肿瘤等疾病的介入治疗 |
| 董成宾 | 博士研究生 | 住院医师 | 门脉高压、肿瘤等疾病的介入治疗 |
| 张裕 | 博士研究生 | 住院医师 | 门脉高压、肿瘤等疾病的介入治疗 |
刘福全等主编的《肝硬化门静脉高压介入治疗经验与技巧》，这是国内第一部有关肝硬化门静脉高压介入治疗的专著。刘福全等主编的《门静脉系统血栓介入治疗经验与经验》，也是国内第一部有关门静脉血栓的介入治疗的专著。
主笔撰写《门静脉系统血栓防治指南》、参与撰写《中国肝静脉压力梯度临床应用专家共识（2018板）》及《门静脉高压诊治专家共识》。培养北大和首医硕士、博士研究生20多名，其中博士生6名。
获得“中国研究型医院杰出中青年人才奖”，所带领的科室被评为“中国研究型医院建设示范学科”,是中国肝炎防治基金会及中国研究型医院学会肝病专委会“肝脏肿瘤与相关疾病微创诊治”培训基地。被授予中央国家机关优秀青年，省部级建功立业奖章获得者，省部级青年科技拔尖人才和优秀学科带头人，北京市卫计委党员之星及奥运微笑大使等称号。
主持国家科技支撑计划项目1项、国家自然科学基金2项、北京市重点项目1项、联合攻关项目1项、北京市科委首特项目8项、其他省部级科研基金资助5项；以第一完成人获中华人民共和国铁道部科技进步奖二等奖1项(证书编号:97010-1)及三等奖1项(证书编号:95105-1)。以第一作者或通讯作者发表文章150余篇，其中SCI文章50余篇(其中10分以上3篇)，影响因子超过100分。
2012
1. Zhu X , Shi W , Tai W , et al. The comparition of biological characteristics and multilineage differentiation of bone marrow and adipose derived Mesenchymal stem cells[J]. Cell & Tissue Research, 2012, 350(2):277-287.
2014
2. Lei W , Fuquan L , Zhendong Y , et al. Interventional treatment of stent restenosis or occlusion after transjugular intrahepatic portosystemic shunt[J]. Journal of Capital Medical University, 2014, 35(1):136-139.
3. He F L , Wang L , Yue Z D , et al. Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients[J]. World Journal of Gastroenterology, 2014, 20(33):11835-11839.
2015
1. Qiu B , Zhao M F , Yue Z D , et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension[J]. World Journal of Gastroenterology, 2015, 21(43):12439-12447.
2. Fu-Liang, Wang, Hong-Wei, et al. Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome[J]. World Journal of Gastroenterology, 2015, 21(8):2413-8.
3. Wang L . Establishment of a hepatic cirrhosis and portal hypertension model by hepatic arterial perfusion with 80% alcohol[J]. World Journal of Gastroenterology, 2015, 21(32).
4. Yao J, Zuo L, An G, et al. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.[J]. Journal of Gastrointestinal & Liver Diseases Jgld, 2015, 24(3):301-307.
2016
1. Fuliang H , Shan D , Zhibo X , et al. Pathological Predictors of Shunt Stenosis and Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt[J]. BioMed Research International, 2016, 2016:1-8.
2. Zhao M , Yue Z , Zhao H , et al. Techniques of TIPS in the treatment of liver cirrhosis combined with incompletely occlusive main portal vein thrombosis[J]. Scientific Reports, 2016, 6:33069.
3. He F , Zhao H , Dai S , et al. Transjugular intrahepatic portosystemic shunt for Budd–Chiari syndrome with diffuse occlusion of hepatic veins[J]. Scientific Reports, 2016, 6:36380.
4. Wang L , Xiao Z , Yue Z , et al. Efficacy of covered and bare stent in TIPS for cirrhotic portal hypertension: A single-center randomized trial[J]. Scientific Reports, 2016, 6:21011.
5. Zhao H , Liu F , Yue Z , et al. Evaluation of mid- and long-term efficacy of shunt limiting for hepatic myelopathy after transjugular intrahepatic portosystemic shunt[J]. Clinics & Research in Hepatology & Gastroenterology, 2016, 40(4):440-446.
2017
1. Qiu B , Li K , Dong X , et al. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus[J]. CardioVascular and Interventional Radiology, 2017, 40(9):1372-1382.
2. Zhao H , Liu F , Yue Z , et al. Association of hepatic vein Lipiodol tram-track sign during transcatheter arterial chemoembolization with perioperative death[J]. Journal of International Medical Research, 2017:030006051770414.
3. Wang L , He F , Yue Z , et al. Techniques and long-term effects of transjugular intrahepatic portosystemic shunt on liver cirrhosis-related thrombotic total occlusion of main portal vein[J]. Scientific Reports, 2017, 7(1):10868.
4. Zhao, Hongwei, Fuquan Liu, Zhendong Yue, Lei Wang, Zhenhua Fan, Yanna Liu, Jialiang Hui, Yi Xiang, and Xiaolong Qi. "Transjugular intrahepatic portosystemic shunt for chronic portal vein thrombosis and incidence of hepatic eeplopathy." Int J Clin Exp Med 10, no. 2 (2017): 3486-3493.
5. Qi, Xiaolong, Yu Zhang, Zhenyuan Ning, Yifei Huang, Jialiang Zou, Sizhe Chen, Chuan Liu et al. "Diagnostic Accuracy of Radiomics-based Hepatic Venous Pressure Gradient for Clinically Significant Portal Hypertension in Cirrhosis." 2017.
6. Zhao H , Liu F , Yue Z , et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt in the treatment of hepatopulmonary syndrome[J]. Medicine, 2017, 96(49):e9080.
2018
1. Qi X , Liu F , Li Z , et al. Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis[J]. Journal of Hepatology, 2017:S0168827817322778.
2. Song T , R?Ssle M , He F , et al. Transjugular intrahepatic portosystemic shunt for hepatorenal syndrome: A systematic review and meta-analysis[J]. Digestive and Liver Disease, 2018:S1590865818301373.
3. Hong-Bin L , Zhen-Dong Y , Hong-Wei Z , et al. Pathological Features of Mitochondrial Ultrastructure Predict Susceptibility to Post-TIPS Hepatic Encephalopathy[J]. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018:1-9.
4. Dong J , He F , Wang L , et al. Iodine density Changes in Hepatic and Splenic Parenchyma in Liver Cirrhosis with Dual Energy CT (DECT): A Preliminary Study[J]. Academic Radiology, 2018.
5. Liu F , Ning Z , Liu Y , et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study[J]. EBioMedicine, 2018.
6. Zhao H , Yue Z , Wang L , et al. Benefits of Early Treatment for Patients with Hepatic Myelopathy Secondary to TIPS: A Retrospective Study in Northern China[J]. Scientific Reports, 2018, 8(1).
7. Qi, Xiaolong, Weimin An, Fuquan Liu, Ruizhao Qi, Lei Wang, Yanna Liu, Chuan Liu et al. "Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension." Radiology 290, no. 2 (2018): 370-377.
8. Wu Y F , Wang T , Yue Z D , et al. Stents combined with iodine-125 implantation to treat main portal vein tumor thrombus[J]. World Journal of Gastrointestinal Oncology, 2018, 10(12):496-504.
2019
1. He, Fu-Liang, Chuan Li, Fu-Quan Liu, and Xing-Shun Qi. "Correlation analysis of collagen proportionate area in Budd-Chiari syndrome: A preliminary clinicopathological study." World journal of clinical cases 7, no. 2 (2019): 130.
2. Zhang, Yue, Yi-Fan Wu, Zhen-Dong Yue, Hong-Wei Zhao, Lei Wang, Zhen-Hua Fan, Fu-Liang He, Tao Wang, and Fu-Quan Liu. "Iodine-125 implantation with transjugular intrahepatic portosystemic shunt for main portal vein tumor thrombus." World Journal of Gastrointestinal Oncology 11, no. 4 (2019): 310.
3. Qi, Xiaolong, Yifan Wu, Chuan Liu, Zhendong Yue, Hongwei Zhao, Lei Wang, Xiaoxue Du, Fuliang He, and Fuquan Liu. "Mo1527–Transjugular Intrahepatic Portosystemic Shunt with 7 Mm Covered Stent Reduces Hepatic Encephalopathy Without Losing Shunt Function for Prevention of Portal Hypertension Rebleeding." Gastroenterology 156, no. 6 (2019): S-1332.
4. Qi, Xiaolong, Lei Wang, Fangze Huang, Chuan Liu, Xinlong Lin, Xiangbo Zeng, Yanna Liu, and Fuquan Liu. "Mo1533–Portal Pressure Gradient Measured Immediately After Transjugular Intrahepatic Portosystemic Shunt Placement: Poor in Predicting Rebleeding in Patients with Portal Hypertension." Gastroenterology 156, no. 6 (2019): S-1334.
5. Qi, Xiaolong, Wenda Li, Pinzhu Huang, Xinlong Lin, Xiangbo Zeng, Yanna Liu, Ruizhao Qi, Fuquan Liu, Yu Wang, and Chunqing Zhang. "Von Willebrand factor a non-invasive serum biomarker of portal pressure in cirrhosis: Evidence in human and rodent." In JOURNAL OF HEPATOLOGY, vol. 70, pp. E823-E824. PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS: ELSEVIER SCIENCE BV, 2019.
文件上传中...
